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Abstract: Overactive bladder syndrome (OAB) is a common condition affecting adults and 
children worldwide, resulting in a substantial economic and psychological burden. Percutane-
ous tibial nerve stimulation (PTNS) is derived from acupuncture used in Chinese traditional 
medicine and was first described in the early 1980s. It is a neuromodulation technique used to 
modulate bladder function and facilitate storage. Being a minimally invasive, easily applicable, 
but time-consuming treatment, future developments with implantable devices might be the 
solution for the logistical problems and economic burden associated with PTNS on the long 
term. This nonsystematic review provides a current overview on PTNS and its effectiveness in 
the treatment of OAB for both adults and children. 
Keywords: overactive bladder, percutaneous tibial nerve stimulation, neuromodulation, electri-
cal stimulation
Introduction
Overactive bladder syndrome (OAB) is a common condition defined as urgency to void, 
usually accompanying frequency and nocturia, with or without urge urinary incontinence 
(UUI), in the absence of urinary tract infection (UTI) or other obvious pathology.1,2 OAB 
with or without UUI affects millions worldwide, with a prevalence ranging from 1.5% 
to 36.4% resulting in a substantial economic and psychological burden.3,4 Health-related 
quality of life (QoL) is usually negatively affected, and patients with OAB experience 
more anxiety and depression compared to healthy controls.4–7 In these patients, social 
stigmatization frequently leads to less self-esteem and impaired interpersonal interac-
tions.8,9 Although the etiology of OAB is multifactorial, some genetic predisposition 
might exist, as there is a reported 2.8 times increased risk for children with mothers 
suffering from OAB.10
Neuromodulation, like sacral nerve stimulation (SNS) and percutaneous tibial nerve 
stimulation (PTNS) of the lower urinary tract, is a second-line treatment option for 
refractory OAB. In theory, neuromodulation should be minimally invasive, easily appli-
cable, and not cause unnecessary embarrassment by stimulating specific areas of the 
body, for example, the genital area. Furthermore, sustainability and cost-effectiveness 
are important in view of the competitiveness with other treatments. 
This nonsystematic review presents a summary of the history and theories on the 
pathophysiology behind neuromodulation, the clinical results, and latest developments 
in PTNS. The aim was to provide an up-to-date overview on PTNS and its effective-
ness in the treatment of OAB.
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Materials and methods
We searched the databases PubMed, MEDLINE, Cochrane, 
and Embase for relevant English-language articles. In addi-
tion, citations from the primary references were scrutinized 
for relevant articles that the databases could not locate. 
A combination of keywords used for the search included: 
percutaneous or posterior tibial nerve stimulation, neu-
romodulation, effectiveness, long-term outcome, patient 
perspectives, prognostic factors, cost-effectiveness, and 
implantable stimulator.
Results 
General principle of neuromodulation
The innervation of the lower urinary tract comes from the 
lumbar, sacral, and coccygeal segmental nerves originating 
from L2-S4. A large network of both afferent and efferent 
fibers is formed after exiting the spinal cord, innervating all 
the pelvic organs. The sciatic nerve is composed of fibers 
from L4 to S3 and descends down toward the lower extremi-
ties.11 One of its distal branches is the posterior tibial nerve 
(PTN). Neuromodulation is postulated to be the effect of 
cross-signaling between sympathetic and parasympathetic 
postganglionic nerve terminals and synapses, causing altera-
tion of nerve signals involved in the voiding reflex. de Groat 
et al12 described this neurophysiological process and the 
neural circuits involved in controlling the lower urinary tract. 
Stimulation of peripheral nerves and subsequent “cross-talk” 
at the level of the postganglionic neuroeffector junctions can 
modulate transmission. This implies that stimulating one area 
of the innervations system seems to alter the nerve behavior 
of other systems, leading to alteration in bladder function by 
stimulating peripheral nerves. The pudendal nerve, the dorsal 
genital nerve, and the PTN are examples of such peripheral 
nerves that can affect bladder behavior. Stimulating overly-
ing skin or dermatomes, instead of actual nerves, is another 
option of peripheral neuromodulation.13–16
Effects on the peripheral nervous system
The mechanism behind neuromodulation is still not com-
pletely understood. Alteration of the afferent and efferent 
pathways between the brain, brain stem, and pelvic organs are 
thought to modulate the voiding reflex and facilitate storage. 
Symptoms of OAB (including UUI) may represent the clini-
cal expression of an alteration of the pelvic neuromuscular 
environment via changes in the inhibitory and excitatory 
signals of the voiding reflex; this has been confirmed in animal 
studies. A normal spinal–brain stem–spinal reflex is seen in 
cats with an intact central nervous system (CNS), activated by 
non-nociceptive Aδ bladder afferent fibers which pass through 
the supraspinal relay stations in the periaqueductal gray (PAG) 
to the pontine micturition center (PMC). The PMC activates 
the efferent pelvic nerve which results in voiding.12,17
This reflex is present even in decerebrated animals, but is 
blocked by the transection of the spinal cord because, then, 
the afferent signals from the bladder cannot go up and the 
efferent signals from the PMC to the bladder cannot go down. 
If the spinal transection is distal to the sacral segments, irriga-
tion of the bladder by diluted acetic acid (AA) unmasks reflex 
contractions mediated by spinal reflex circuitry activated 
C fiber bladder afferents instead of non-nociceptive Aδ blad-
der afferent fibers.18 It is postulated that detrusor overactivity 
(DO) in OAB is mediated through these C fibers.19,20 
Animal studies have shown different effects of SNS, 
pudendal nerve stimulation (PNS) or tibial nerve stimulation 
(TNS) on voiding reflex pathways each including different 
neurotransmitter mechanism.21,22 In decerebrate cats under 
anesthesia, DO was evoked by direct electrical stimulation 
(ES) of the PMC, activating the excitatory efferent output from 
PMC to the bladder. Subsequently, PNS or TNS followed. 
PNS but not TNS was able to inhibit PMC-induced DO. Fur-
thermore, propanolol (a non-selective B-adrenergic receptor 
antagonist) completely eliminated PNS-induced inhibition 
of DO. On the contrary, TNS facilitated PMC-induced DO 
and was blocked by propanolol. The authors concluded that 
B-adrenergic receptors are mainly involved in PNS-induced 
inhibition of DO acting on the efferent pathway of the void-
ing reflex while TNS might use the same receptors for the 
opposite effect, that is, facilitation of DO. Instead of influenc-
ing the efferent pathway of the voiding reflex like PNS, the 
inhibitory effect of DO after TNS is believed to be the effect 
of modulation of the afferent pathway. Strong inhibition of 
the ascending sensory pathway and weak excitation of the 
excitatory efferent pathway will result in the overall inhibition 
of DO seen after TNS.22
While B-adrenergic receptors are thought to play a major 
role in PNS, opioid receptors and endogenous enkephalins 
seem to be important in the mechanism behind TNS. In cats 
with an intact CNS, intravenous naloxone (opioid receptor 
antagonist) blocked the TNS-induced inhibition of DO after 
AA bladder installation, the latter representing a model for 
OAB. Nalaxone was unable to block TNS-induced inhibition 
of normal reflex bladder activity provoked by saline bladder 
instillation.18 Tai et al also studied the role of nalaxone admin-
istration in TNS-induced inhibition of DO in cats. Nalaxone 
was able to block TNS-induced inhibition of DO after AA 
installation but, furthermore, did not change cystometric 
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 U
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 0
6-
De
c-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Urology 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
147
PTNS treatment for OAB
bladder capacity (CMC). On the contrary, nalaxone was 
unable to alter TNS-induced normal bladder reflex activity 
after saline installation but reduced CMC instead.23 Nalaxone 
could not alter PTNS-induced inhibition but reduced CMC, 
indicating that the voiding reflex was inhibited by the activa-
tion of opioid receptors and endogenous enkephalins. On the 
contrary, nalaxone suppressed PTNS-induced inhibition after 
AA installations but did not alter CMC, indicating that the 
enkephalinergic inhibition was inactive during AA-induced 
DO, but was activated by PTNS. This supports the idea that 
bladder activity in OAB is mediated through afferent C fibers 
being nociceptive, while normal reflex bladder activity is 
mediated through Aδ afferent fibers. Saline installations 
activate non-nociceptive Aδ afferent fibers which, in their 
turn, trigger a spinobulbospinal bladder reflex transmitted 
through the PAG and PMC. On the other hand, AA irritation 
of the bladder activates nociceptive C fibers that facilitate 
the supraspinal reflex. Enkephalinergic mechanisms are not 
involved in the control of the C-fiber-mediated spinal reflex, 
but are involved in the inhibitory modulation of this reflex 
induced by PTNS.23
Li et al24 implanted a sacral nerve stimulator in 7 pigs 
and evoked DO bladder by AA instillations. Consecutive 
cystograms at baseline, after infusion of AA and after SNS, 
were performed with or without intravenous naloxone and 
tramadol infusion. Remarkably, SNS combined with tramadol 
had a significantly better effect on CMC than SNS alone, sug-
gesting the anti-nociceptive effect and subsequent inhibition 
of DO while naloxone blocked the effect of SNS leading to 
a decreased CMC.24 
Effects on the CNS
Blok et al studied the effects of acute and chronic SNS on 
the brain using positron emission tomography images.25 
Areas located in the right postcentral gyrus, left parietal 
cortex, right insula, and medial prefrontal cortex showed 
increased cerebral blood flow during acute SNS in newly 
implanted patients. Furthermore, increased activation in the 
ventromedial-orbitofrontal cortex and decreased activation in 
the left medial cerebellum occurred. This suggests modula-
tion of areas involved in sensorimotor learning when starting 
SNS. During chronic SNS, there was decreased activity in 
the cerebellum, midbrain, and adjacent thalamus and limbic 
cortical areas, areas previously implicated in the control of 
bladder contractions, awareness of bladder filling, and initia-
tion of voiding. This implies that different areas in the brain 
are involved in the learning process and start of SNS, which 
are taken over by other areas in the brain as time passes, 
resulting in a shift from dysfunctional to normal control of 
the voiding reflex.
Information processing in the brain after peripheral nerve 
stimulation can be visualized measuring somatosensory 
evoked potentials (SEPs). Especially long-latency somato-
sensory evoked potentials (LL-SEPs) seem to provide infor-
mation on the function of somatosensory associative cortical 
structures. The presence of reproducible LL-SEPs are likely 
to be responsible for the neuroplastic changes induced by 
neuromodulation.26 Finazzi-Agro et al27 studied this more 
thoroughly. Both short-latency SEP (SL-SEP) and LL-SEPs 
were recorded after peripheral or sham stimulation.27 Peak 
latency and peak-to-peak amplitude of so-called P80, P100, 
and P200 waves were measured at baseline and at the end of 
(sham) stimulation. Mean latency of the previously mentioned 
waves and the mean amplitude of P200 waves did not change 
significantly. However, the amplitude of LL-SEP changes of 
especially P80 and P100 waves in the active PTNS group 
was significantly higher as compared to the sham group. The 
recorded P80 and P100 amplitude increase suggests long-term 
modifications in the synaptic efficiency of the somatosensory 
pathway. Long-term potentiation and depression of excitatory 
synaptic transmission can contribute to experience-dependent 
modifications of the brain, including learning and memory.27 
This confirms the idea of the re-organization of the cortical 
network as a result of peripheral neuromodulation.
History of PTNS
Peripheral neurostimulation is derived from techniques used 
in traditional Chinese medicine, better known as acupuncture. 
Acupuncture was already practised during the Stone Age. 
The earliest writings about “stone needles” (called Pien in 
Chinese) date from about 500 BC. Puncturing specific points 
was believed to restore “the energetic harmony” of the body.28 
In 1673, a Dutch physician (Wilhelmus ten Rhyne) discovered 
this Eastern traditional way of medicine which he published in 
a book entitled Dissertatio de Arthritide: Mantissa Schemat-
ica: De Acupunctura: Et Orationes tres. In this book, he was 
the first Western person to describe the technique he called 
“acupunctura,” in which needles were used to treat diseases. 
One of the most commonly used acupuncture points is the 
San-Yin-Jiao point or Spleen 6 (SP-6). This is located on the 
medial side of the lower leg, about 4 finger breadths cepha-
lad to the medial malleolus. The location of the SP-6 point 
and the organs affected by its stimulation have remarkable 
similarities with PTNS (Figure 1). When an electrical current 
is applied to the acupuncture needle, the technique is called 
electrical acupuncture. Especially when electroacupuncture 
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is performed with similar stimulation parameters (2–15 Hz, 
10–20 mA), it resembles PTNS.29 The main difference lies 
in the actual anatomical substrate used in PTNS, instead of 
“energy pathways” stimulated in acupuncture.
Before the introduction of PTNS, SNS was the main 
neuromodulation technique used. SNS was developed by 
Tanagho and Schmidt in the late 1980s, and the first device 
was implanted in Europe in 1989. At first, it was believed 
that stimulation would lead to actual contraction of the 
pelvic floor and sphincter complex to prevent urinary leak-
age. Instead, during urodynamic studies, it actually led to 
the inhibition of DO. Nowadays, SNS is an evidence-based 
clinical tool for patients with OAB or non-obstructive 
retention.30,31 After SNS was introduced, the next aim was 
to develop more easily accessible and less invasive tech-
niques, such as PTNS.
McGuire et al were the first to describe PTNS in 1983. 
In 22 patients with neurogenic OAB, TNS was applied 
and 87% showed complete or partial improvement of their 
symptoms.32 Subsequently, Stoller et al further developed 
PTNS, also known as Stoller afferent nerve stimulation 
(SANS), as a treatment for OAB in pig-tailed monkeys 
and, later, in humans, with promising results.33 This new 
initiative was the start of the worldwide development and 
exploration of PTNS.
Technique 
PTNS is given in supine position with the medial malleolus 
pointing upwards. In children, previous administration of a 
topical anesthetic agent (eg, lidocaine) can help to reduce 
pain and fear associated with needle insertion. A 34-gauge 
stainless steel needle is inserted ~3 finger breadths cephalad 
to the medial malleolus, between the posterior margin of the 
tibia and soleus muscle (Figure 1). The goal is to place the 
tip of the needle close to the PTN without actually touching 
it. Given the varying size of ankles, the optimal depth and 
angulation may be varied. On average, insertion depth is 
about 2–4 cm with an angulation of 60°–90°. A stick elec-
trode is placed on the same leg near the arch of the foot. The 
needle and the electrode are connected to a low voltage (9 V) 
stimulator (Urgent PC®; Cogentix Medical Inc., Minnetonka, 
MN, USA) with an adjustable pulse intensity of 0–10 mA, 
a fixed pulse width of 200 microseconds, and a frequency 
of 20 Hz (Figure 1). 
Stimulation of the PTN leads to effects in both efferent 
and afferent nerve fibers. Flexion of the great toe, or fan-
ning, is a result of an efferent effect. The sensory afferent 
effect is a radiation tickling sensation of the foot sole. 
During the initial test stimulation, the amplitude is slowly 
increased until the large toe starts to curl, or toes start to 
fan. If the patient complains about discomfort or “buzzing” 
Figure 1 Drawing showing the location of the Sanyinjiao point, or Spleen 6 (SP-6), the percutaneous tibial nerve stimulation (PTNS) point, and the technical details.
Pulse intensisty adjustable: 0–10 mA
Pulse width fixed: 200 ms
Frequency 20 Hz
PTNS needle insertion
three fingerbreadths above
the tip of the malleolus
Medial malleolus
Sanyinjiao point (SP-6)
four fingerbreadths above
the tip of the malleolus
Posterior tibial nerve
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immediately around the needle site, the needle may not 
be deep enough. In contrast, the needle may be too close 
to the PTN if the stimulation is extremely uncomfortable. 
Needle repositioning or reinsertion at the ipsilateral or 
contralateral ankle is advised. Once optimal position is 
assured, stimulation is applied at an intensity level well 
tolerated by the patient and can be increased or decreased 
during the treatment.34
Most treatment schedules consist of 12 outpatient con-
secutive treatment sessions lasting 30 minutes each, given 
1–3 times per week.35,36
Clinical results
Since its introduction, many clinical trials have used PTNS 
to treat either OAB or non-obstructive urinary retention. 
Outcomes in these studies are mainly based on frequency 
voiding charts (FVCs) and QoL questionnaires.34,37–39 Overall 
subjective success, defined as improved QoL or willingness 
to continue treatment, was found in 56%–63%. Overall 
objective success with ≥50% decrease in urge or UUI and 
25% reduction in daytime and/or nighttime frequency was 
found in 33%–71%.34,37–39
Urodynamics done to provide more objective data show 
conflicting results. PTNS performed in eight neurological 
patients as soon as DO was observed during cystometry 
failed to suppress detrusor contractions.40 However, another 
study showed a significant increase in both the volume of the 
first involuntary DO and the mean CMC in 29 patients with 
multiple sclerosis stimulated with PTNS.41 Studies examining 
pre- and posttreatment urodynamic data in non-neurogenic 
OAB also show contradictory results. Vandonick et al found 
complete suppression of DO in only a few cases, while others 
report elimination of DO in 76.9%.42,43 Nevertheless, in both 
these studies, CMC increased significantly. Furthermore, 
patients without DO at baseline were 1.7 times more prone to 
respond to PTNS than those with urodynamic proven DO.42
Peters et al performed the pivotal study on PTNS. In a 
multicenter, double-blind randomized controlled trial (RCT) 
(SUmiT trial), 12 weeks of PTNS was compared to sham 
stimulation. This was the first study including a validated 
sham arm providing more information on the placebo effect. 
In total, 220 patients were included. Outcome parameters 
were improvement in global response assessment (GRA), 
frequency voiding charts (FVC) data, and QoL. The GRA is 
a self-reported 7-point scale measuring the individual percep-
tion of treatment changes. Success was defined as moderate 
or marked improvement in the GRA. Patients receiving PTNS 
showed 55% moderate or marked improvement compared 
to 21% in the sham group. After 12 weeks, FVC parameters 
showed significant improvements in frequency, nocturia, 
voids with moderate/severe urgency, and UUI in the PTNS 
group compared to the sham group.36 Finazzi-Agro et al per-
formed another sham-controlled RCT with similar results.35
Interestingly, there is no standardized treatment regimen. 
Different protocols are described (3, 6, 8, 12 weeks) with the 
most objective data to be in favor of the 12-week regimen 
based on previously mentioned RCTs.35,36 However, in the 
study of Peters et al weekly sessions were given compared 
to sessions 3 times a week in the study of Finazzi-Agro et al. 
Given the fact that both the studies show positive results, 
stimulation once a week seems to be effective and less time-
consuming. Shorter schedules are reported by Yoong et al who 
found an overall 67.5% positive response in 43 women who 
received a shortened 6-week PTNS treatment protocol with 
a 50% symptom reduction and a 25% improvement in QoL, 
which is broadly comparable to the conventional 12-week 
results.44 However, with the 6-week regimen, the median 
time to relapse was 3 weeks so the authors concluded that 
it was more cost-effective to provide 12 weekly sessions in 
newly diagnosed patients. 
While most objective data published favor a 12-week 
protocol, shortened regimes might also be effective, but 
perhaps less sustainable. Until further data are published, 
treatment protocols remain mainly dependent on individual 
patient–physician preferences.
Relapse of symptoms after successful treatment is likely 
to occur after PTNS. In a study on 11 patients with a suc-
cessful outcome of 12-week PTNS, an interval of 6 weeks 
without stimulation was introduced. After this interval, 7 of 
11 (63%) experienced a ≥50% worsening of their complaints, 
which returned to baseline after re-starting PTNS.45 
Yoong et al44 published the 2-year follow-up of 23 patients 
without deterioration of initially achieved results if a main-
tenance schedule of PTNS was given. Their study consisted 
of an open-door policy whereby patients could receive PTNS 
whenever they felt it necessary. A median of 8.42 treatments 
per year with a median length between the treatments of 64.3 
days was given. Nocturnal frequency decreased with 57%. 
Daytime frequency and UUI episodes at 2 years were signifi-
cantly lower than at pretreatment (6.6 vs 11.8 and 2.0 vs 3.5, 
respectively; p<0.05) and comparable to those at 6 weeks. 
The median satisfaction score after 2 years of maintenance 
PTNS therapy was comparable to that recorded at 6 weeks 
(7.25/10 vs 9.6/10; p=0.25).44 
Peters et al46 followed 50 participants from the SUmiT 
Trial who met the primary effectiveness endpoint after 
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12 weekly PTNS. These patients were prescribed a fixed-
schedule 14-week tapering protocol followed by a personal 
treatment. Of this group, 29 patients completed the 36-month 
protocol receiving a median of 1.1 treatments per month. At 
3 years, 77% remained relapse free with 8.7 median voids 
per day (baseline 12.0) and 0.3 UUI episodes per day (base-
line 3.3). QoL remained markedly improved from baseline 
through 3 years.46 Other studies confirm sustainability with 
a maintenance schedule.47,48 Maintaining PTNS once every 2 
or 3 weeks seems to be sufficient to sustain therapeutic effect 
in those patients who benefit from PTNS. 
Side effects
From the studies examined, it was found that PTNS has no 
serious adverse events. Side effects described in the literature 
are mild and mainly related to needle insertion, bruising 
(0.9%), discomfort (1.8%), and slight bleeding.34–36 
PTNS compared to other treatments
Several studies aimed to establish the effectiveness of PTNS 
compared to other treatments (Table 1). Two RCTs compared 
PTNS versus tolterodine in patients with non-neurogenic 
OAB.49,50 UUI decreased significantly after 3 months in 
both the groups and QoL increased. However, in both the 
RCTs, no significant difference was seen between both the 
treatments regarding QoL, 24-hour voiding episodes and 
UUI. Fewer side effects were seen in the PTNS group.49,50 
Other antimuscarinics compared to PTNS yielded similar 
outcomes.14,51 A large Cochrane review compared seven 
trials with various types of peripheral neuromodulation 
(intravaginal ES, PTNS/SANS, and transcutaneous nerve 
stimulation) to antimuscarinics. Subjective improvement 
rates were observed in favor of ES. In 54%, no improvement 
was seen with antimuscarinics versus 33% with ES (risk 
ratio 0.64, 95% CI 1.15–2.34). However, this was significant 
only for PTNS (risk ratio 2.21, 95% CI 1.13–4.33) and was 
not supported by significant changes in voiding parameter 
or QoL. The authors concluded that antimuscarinics were a 
well-established therapy for OAB, and limited evidence from 
small trials might suggest ES to be a better option in patients 
refractory to antimuscarinics.52 
A subsequent Cochrane review compared ES with non-
implantable electrodes for OAB to no treatment or other 
available treatments. They included 63 studies and found 
moderate-quality evidence indicating that ES was better for 
the perception of improvement of OAB symptoms than pelvic 
muscle floor training (PMFT) (risk ratio [RR] 1.60, 95% CI 
1.19–2.14), drug treatment (RR 1.20, 95% CI 1.04–1.38) and 
placebo or sham treatment (RR 2.26, 95% CI 1.85–2.77). 
The authors concluded that ES has better results than PMFT. 
Low evidence suggested participants receiving ES plus 
PMFT, compared to PMFT training alone were more likely 
to report improvement in UUI (RR 2.82, 95% CI 1.44–5.52). 
They concluded that ES shows promising results compared 
to no treatment, placebo/sham treatment, PMFT, and drug 
treatment and that adding ES to other treatments might be 
beneficial.53
Sancaktar et al54 also studied PTNS as part of a multi-
modal treatment. They compared antimuscarinics with or 
without PTNS in 40 women with OAB. Frequency decreased 
from 12.8±1.3 at baseline to 6.4±0.6 in the antimuscarinics 
group and 12.2±1.2 to 4.5±0 in the antimuscarinics/PTNS 
group (p<0.05). Urgency, UUI, and QoL improved in both the 
groups but was significantly better if multimodal treatment 
was given.54 In a study by Karademir et al, the combina-
tion of PTNS and oxybutinine led to an overall response of 
83.2% compared to 61.6% response rate with PTNS alone; 
however, this difference was not significant (p=0.24).55 Other 
studies were also unable to confirm the additional effects of 
antimuscarinics with PTNS.56
Patients with OAB, especially when refractory to first-line 
treatments, pose a therapeutic challenge. Efficacy of anti-
muscarinics may be limited by their intolerable side effects 
and/or inadequate response. Furthermore, a high number of 
patients discontinue antimuscarinics on the long term. One 
study showed that the adherence rates for tolterodine and 
oxybutinine after 12 months were 9% and 6%, respectively.57 
PTNS might be a good alternative treatment. Other options 
include SNS or Botox. However, to our knowledge, no RCT 
has compared these second-line treatments.
Prognostic factors for PTNS
Few data are available on the prognostic factors for PTNS. 
Urodynamic studies in patients with OAB receiving PTNS 
suggest better treatment outcome in those patients without 
actual DO.42 In a study of 132 patients, numerous clinical 
parameters were evaluated and most of them could not 
reveal any prognostic value.58 Even a history of sexual and/
or physical abuse did not alter PTNS treatment outcome. 
The only factor that seemed to show any influence was a 
low total score at baseline in the SF-36 general QoL ques-
tionnaire. This proved to be predictive for not obtaining 
objective or subjective success. Patients with a low SF-36 
Mental Component Summary were especially prone to 
fail. These patients also scored worse on disease-specific 
QoL questionnaires, despite that they had no difference 
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in disease severity compared to patients with good mental 
health.58 
Therefore, mental health questionnaires might be helpful 
as an additional tool to select optimal candidates for PTNS.
Patient perspectives
Some studies evaluated actual patient preferences concerning 
treatment options for refractory OAB.59,60 A best-worst scal-
ing, together with surveys with different individual attributes, 
was used to assess the preferences of 245 patients from the 
USA and the UK. Most patients (98.8%) were willing to try 
at least one of the different treatments. On a scale from 0% to 
100%, the mean percentage likelihoods of trying SNS, Botox, 
and PTNS were 45%, 43%, and 62%, respectively. The main 
attributes in general considered important in decision-making 
were “lasting improvement,” “minimal side effects,” and “send 
signals to the brain.” Worst-rated attributes were “be willing 
to catheterize” and “complications of implant.” However, 
preferences for the attributes differed mainly based on which 
treatment patients preferred; for example, patients preferring 
PTNS favored the attributes “needle insertion in the ankle” and 
“multiple visits required” more than patients favoring SNS.59,60 
Thus, incorporation of a decision tool addressing these 
attributes might help patients to increase compliance, treat-
ment effect, and satisfaction.
Cost-effectiveness
Patient with refractory OAB remain a therapeutic challenge, 
and the effectiveness of second-line treatment options should 
be weighed against their costs. An economic model compar-
ing SNS with Botox was developed using a probabilistic 
Markov analytic model in Dutch patients with refractory 
OAB. Different modeling scenarios were used. The 5-year 
costs were € 25,780 for SNS and € 19,353 for Botox, lead-
ing to € 6,428 additional costs per patient for SNS. SNS 
became cost-effective (incremental cost-effectiveness ratio 
[ICER] <40,000) from the third yearly treatment of Botox 
onward if given under general anesthesia.61 A comparable 
study conducted in Italy calculated the 10-year costs for 
SNS at € 32,975 versus € 33,309 for Botox, with cumula-
tive quality-adjusted life years (QALYs) of 7.52 and 6.93, 
respectively. It was concluded that the relatively higher initial 
costs of early SNS can be offset by the favorable long-term 
outcomes.62 Staskin et al63 compared the costs of different 
treatment modalities for OAB in the USA. PTNS was the 
least costly ($4,999 for a 3-year treatment), followed by Botox 
($7,651) and SNS ($26,269) for the same treatment period.63 
Martinson et al also concluded that PTNS had substantially 
lower costs compared to SNS in the USA. Furthermore, an 
additional 1% of patients would remain on therapy at 2 years 
if SNS was used rather than PTNS, but average additional 
costs per patient would be >$500,000.64 Despite variation 
between countries PTNS appears not to be cost-effective as 
a primary treatment option compared to antimuscarinics but 
might be a good alternative in therapy refractory patients. 
However, on the long term, SNS might be more cost-effective 
considering the necessity of repeated clinical visits for PTNS. 
Implantable PTNS 
While maintenance therapy seems necessary to sustain 
therapeutic effect, soon after its clinical introduction, it was 
realized that repeated visits would finally lead to a logistic 
problem. Besides overfull clinics, the travel burden for 
patients would be high and PTNS treatment-on-demand 
would be impossible. Transcutaneous stimulation was tried 
with surface electrodes, but results indicate that it might be 
less effective because of the impendence of the skin.65 A 
new promising development came with the introduction of 
an implantable stimulator near the ankle. Van der Pal et al66 
were the first to study the subcutaneous implant Urgent-SQ 
(Uroplasty, Inc, Minnetonka, MN, USA) in 8 patients with 
refractory OAB. The Urgent-SQ was surgically implanted 
~5 cm above the medial malleolus near the PTN, without 
actually exposing it. During the procedure, the implant was 
activated to confirm the correct position. Motor and sensory 
responses were evaluated postoperatively at day 10 and after 
3–6–12 months. The primary objective was ≥50% reduction 
in the number of UUI and/or voids on bladder diary. At 3, 
6, and 12 months, 5, 6, and 4 patients, respectively, met the 
primary objective. At 3- and 6-month follow-up, voiding and 
QoL parameters had significantly improved in these patients; 
at 12 months, it remained stable compared to 6 months. UTI 
temporary walking difficulties and spontaneous radiating 
sensations were reported as adverse events, and there was 
no local infection, erosion, or dislocation. As in studies 
concerning sacral stimulation, not all patients who respond 
well to PTNS have similar results with implantable devices. 
For example, in one patient, the implant was removed after 
12 months because of technical failure. During the proce-
dure, the implant was activated which did not result in a 
motor response. The device was examined but results not 
mentioned.66
Janssen et al67 published the long-term efficacy and safety 
of these patients in an open-label study. The 7 patients with 
the implant still in situ were contacted after 9 years and 
evaluated with an interview, physical examination, ankle 
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X-ray, FVC, questionnaires addressing adverse events, per-
formance, efficacy, safety, and QoL. Results showed that 6 
of the 7 patients still had sensory and locomotor responses 
on stimulation at 9-year follow-up. Also, 3 patients, who 
had a successful treatment response at 1 year, still used the 
device. The implants were intact without migration and/or 
displacement; 2 patients experienced minor discomfort. The 
conclusion was that, after 9 years, the Urgent-SQ implant 
was a safe device and well tolerated.67 
Results of a new tibial implanted device (BlueWind 
Medical, Herzliya, Israel) have recently been published.68 
The installation procedure resembled that of the Urgent-
SQ. For the 15 patients in whom the device was implanted, 
a significant improvement was seen in both frequency and 
UUI. At 3-months follow-up, a significant change was seen 
in 24-hour voiding frequency from a mean 11.8 (SD 3.5) to 
8.1 (SD 2.0) per day (p=0.002). The number of severe UUI 
episodes decreased from 2.8 (SD 5.2) to 0.3 (SD 0.4) episodes 
a day (p=0.017). After implantation, 3 patients had prolonged 
antibiotic treatment and 3 patients needed prolonged pain 
treatment for 1 week. In 1 patient, the device was explanted 
due to pain and swelling suspicious for infection, although 
tissue cultures did not reveal a bacterial infection.68
Implantable devices are well tolerated and safe without 
long-term complications. Although pilot studies show prom-
ising results, more research is necessary to establish further 
therapeutic value. 
PTNS in children
OAB is also common in the pediatric population aged 6–16 
years. If standard treatment options (eg, urotherapy, PMFT, 
and antimuscarinics) fail, PTNS might be a good option. 
De Genarro et al69 found that PTNS was well tolerated in 
23 children (4–17 years) with refractory lower urinary tract 
symptoms (LUTS). In 71%, symptoms improved and low 
scores on the visual analog scale for pain were noted, which 
decreased even further during the 12-week treatment period.69 
Several sham-controlled studies have been conducted using 
(mainly) transcutaneous stimulation. In a double-blind RCT, 20 
children with refractory OAB were given either transcutaneous 
TNS or sham treatment for 12 consecutive weeks. Pre- and 
post-urodynamic parameters were compared, and UUI were 
noted and scored with a range of 0–13 (from good to poor). 
Clinical results were defined as poor (≤3-point decrease), 
medium (3–5-point decrease), good (6–8-point decrease), 
and very good (final score of 0–3). In the PTNS group, very 
good results were seen in 45% compared to 66% in the sham 
group, and poor results in 45% versus 33%, respectively. 
Urodynamic parameters revealed significant improvement of 
volume voided during urgency (184–265 mL), maximum CMC 
(215–274 mL), and volume at onset of first DO (48–174 mL). 
The authors stated that, even though urodynamic data show 
improvement, subjective data remain the same and the placebo 
effect plays an important role.70 In a study by Hagstroem et al 
parasacral stimulation was compared with sham treatment. 
After 4 weeks of intervention, 61% reported a decrease in 
incontinence severity versus only 2% in the sham group. How-
ever, no differences were seen in maximal and average voided 
volumes or urodynamic data.71,72 Another group studied the 
additional effect of parasacral stimulation in patients receiving 
urotherapy;73 62 children with OAB were randomized either 
to urotherapy alone or combined with parasacral stimulation. 
In the standard group, 46% were completely dry versus 67% 
in the combined group; this was not significant. Furthermore, 
no differences were seen between both the groups concern-
ing FVC parameters. The authors concluded that parasacral 
stimulation had no additional effect.73
Long-term outcome seems to be good in children treated 
with PTNS. In 44 children with LUTS, the cure rate after 
1 year was 41% if being treated for OAB and 71% if being 
treated for dysfunctional voiding both defined according 
to the International Children’s Continence Society,1 which 
remained stable after 2 years. Maintenance treatment was 
necessary in 29% of children with dysfunctional voiding and 
in 50% of children with OAB.74
Only one study compared PTNS versus parasacral stimu-
lation and found a higher complete resolution of symptoms 
in the parasacral group versus the PTNS group (71% vs 9%) 
without significant differences in scores of urgency and UUI. 
However, because this was not an RCT, the data have to be 
interpreted with caution.13
Transcutaneous/percutaneous stimulation seems feasible 
in children with refractory LUTS. However, more trials with 
larger groups are necessary to determine the actual subjec-
tive and objective effect, while current data show conflicting 
results.
Potential limitations
Because this review has a non-systematic design, there are 
some limitations. Although a comprehensive search was 
made to include eligible articles, some potential articles 
could have been missed. Especially relevant non-English 
language studies might not have been included. Also, no 
methodological assessment or data extraction was done 
to detect heterogeneity or publication bias. Therefore, our 
conclusion needs to be interpreted with caution.
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Conclusion
PTNS can indeed modulate the voiding and storage 
function of the bladder leading to an overall subjective 
improvement of symptoms in about 60% of the patients 
and 47%–56% improvement of FVC parameters with 
sustainable outcome on the long run. The placebo effect 
(subjective improvement measured by patients who actu-
ally received sham treatment) is about 21% and may be 
even higher in children. This might be explained by the 
regular visits, peer-grouping, and/or the weekly attention 
paid to their problem by the caregivers. PTNS seems not 
to be cost-effective as a primary treatment compared to 
antimuscarinics, but is a good treatment option in refractory 
OAB or when antimuscarinics are not tolerated. Although 
PTNS is minimally invasive and not costly, it is time con-
suming. Therefore, new techniques with implants are being 
explored and show initially promising results.
Disclosure
Dr Heesakkers received grants and personal fees from 
Bluewind. The authors report no other conflicts of interest 
in this work.
References
 1. Austin PF, Bauer SB, Bower W, et al. The standardization of terminol-
ogy of lower urinary tract function in children and adolescents: update 
report from the standardization committee of the International Children’s 
Continence Society. Neurourol Urodyn. 2016;35(4):471–481.
 2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogyne-
cological Association (IUGA)/International Continence Society (ICS) 
joint report on the terminology for female pelvic floor dysfunction. 
Neurourol Urodyn. 2010;29(1):4–20.
 3. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global 
prevalence and economic burden of urgency urinary incontinence: a 
systematic review. Eur Urol. 2014;65(1):79–95.
 4. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. 
Comorbidities and personal burden of urgency urinary incontinence: a 
systematic review. Int J Clin Pract. 2013;67(10):1015–1033.
 5. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. 
Urinary incontinence and its relationship to mental health and health-
related quality of life in men and women in Sweden, the United King-
dom, and the United States. Eur Urol. 2012;61(1):88–95.
 6. Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary 
incontinence and overactive bladder: a systematic literature review. 
Urology. 2010;75(3):491–500.
 7. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary 
incontinence and depression. J Urol. 1999;162(1):82–84.
 8. Bower WF. Self-reported effect of childhood incontinence on quality 
of life. J Wound Ostomy Continence Nurs. 2008;35(6):617–621.
 9. Natale N, Kuhn S, Siemer S, Stockle M, von Gontard A. Quality of life 
and self-esteem for children with urinary urge incontinence and voiding 
postponement. J Urol. 2009;182(2):692–698.
10. Sampaio AS, Fraga LG, Salomao BA, et al. Are lower urinary tract 
symptoms in children associated with urinary symptoms in their moth-
ers? J Pediatr Urol. 2017;13(3):e1–269.e6.
11. de Groat WC, Yoshimura N. Anatomy and physiology of the lower 
urinary tract. Handb Clin Neurol. 2015;130:61–108.
12. de Groat WC, Griffiths D, Yoshimura N. Neural control of the lower 
urinary tract. Compr Physiol. 2015;5(1):327–396.
13. Barroso U Jr, Viterbo W, Bittencourt J, Farias T, Lordelo P. Posterior 
tibial nerve stimulation vs parasacral transcutaneous neuromodulation 
for overactive bladder in children. J Urol. 2013;190(2):673–677.
14. Manriquez V, Guzman R, Naser M, et al. Transcutaneous posterior tibial 
nerve stimulation versus extended release oxybutynin in overactive 
bladder patients. A prospective randomized trial. Eur J Obstet Gynecol 
Reprod Biol. 2016;196:6–10.
15. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Ran-
domized trial of transcutaneous tibial nerve stimulation to treat urge 
urinary incontinence in older women. Int Urogynecol J. 2010;21(9): 
1065–1070.
16. Bower WF, Moore KH, Adams RD, Shepherd R. A urodynamic study 
of surface neuromodulation versus sham in detrusor instability and 
sensory urgency. J Urol. 1998;160(6 Pt 1):2133–2136.
17. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. 
Nat Rev Neurosci. 2008;9(6):453–466.
18. Ferroni MC, Slater RC, Shen B, et al. Role of the brain stem in tibial 
inhibition of the micturition reflex in cats. Am J Physiol Renal Physiol. 
2015;309(3):F242–F250.
 19. Fall M, Lindstrom S. Electrical stimulation. A physiologic approach to the 
treatment of urinary incontinence. Urol Clin North Am. 1991;18(2):393–407.
20. Liao KK, Chen JT, Lai KL, et al. Effect of sacral neuromodulation 
on the spinal nociceptive reflex of patients with idiopathic overactive 
bladder. Neuromodulation. 2008;11(1):50–55.
21. Bandari J, Bansal U, Zhang Z, et al. Neurotransmitter mechanisms 
underlying sacral neuromodulation of bladder overactivity in cats. 
Neuromodulation. 2017;20(1):81–87.
22. Lyon TD, Ferroni MC, Kadow BT, et al. Pudendal but not tibial nerve 
stimulation inhibits bladder contractions induced by stimulation of 
pontine micturition center in cats. Am J Physiol Regul Integr Comp 
Physiol. 2016;310(4):R366–R374.
23. Tai C, Larson JA, Ogagan PD, et al. Differential role of opioid receptors 
in tibial nerve inhibition of nociceptive and nonnociceptive bladder 
reflexes in cats. Am J Physiol Renal Physiol. 2012;302(9):F1090–F1097.
24. Li X, Liao L, Chen G, Wang Z, Deng H. Involvement of opioid receptors 
in inhibition of bladder overactivity induced by sacral neuromodulation 
in pigs: a possible action mechanism. Neurourol Urodyn. 2016:1–7.
25. Blok BF, Groen J, Bosch JL, Veltman DJ, Lammertsma AA. Differ-
ent brain effects during chronic and acute sacral neuromodulation in 
urge incontinent patients with implanted neurostimulators. BJU Int. 
2006;98(6):1238–1243.
26. Braun PM, Baezner H, Seif C, et al. Alterations of cortical elec-
trical activity in patients with sacral neuromodulator. Eur Urol. 
2002;41(5):562–566; discussion 566–567.
27. Finazzi-Agro E, Rocchi C, Pachatz C, et al. Percutaneous tibial nerve 
stimulation produces effects on brain activity: study on the modifica-
tions of the long latency somatosensory evoked potentials. Neurourol 
Urodyn. 2009;28(4):320–324.
28. Stux G. General standards in acupuncture treatment of chronic pain. 
Schmerz. 1997;11(2):126–127.
29. Minni B, Capozza N, Creti G, De Gennaro M, Caione P, Bischko J. 
Bladder instability and enuresis treated by acupuncture and electro-
therapeutics: early urodynamic observations. Acupunct Electrother 
Res. 1990;15(1):19–25.
30. van Voskuilen AC, Oerlemans DJ, Weil EH, de Bie RA, van Kerrebroeck 
PE. Long term results of neuromodulation by sacral nerve stimulation 
for lower urinary tract symptoms: a retrospective single center study. 
Eur Urol. 2006;49(2):366–372.
31. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of 
sacral neuromodulation therapy for urinary voiding dysfunction: out-
comes of a prospective, worldwide clinical study. J Urol. 2007;178(5): 
2029–2034.
32. McGuire EJ, Zhang SC, Horwinski ER, Lytton B. Treatment of motor 
and sensory detrusor instability by electrical stimulation. J Urol. 
1983;129(1):78–79.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 U
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 0
6-
De
c-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Urology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
156
de Wall and Heesakkers
33. Stoller ML, Copeland S, Millard RJ, Murnaghan GF. The efficacy of 
acupuncture in reversing the unstable bladder in pig-tailed monkeys. 
J Urol. 1987;137(4):A104–A104.
34. Govier FE, Litwiller S, Nitti V, Kreder KJ Jr, Rosenblatt P. Percutaneous 
afferent neuromodulation for the refractory overactive bladder: results 
of a multicenter study. J Urol. 2001;165(4):1193–1198.
35. Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. 
Percutaneous tibial nerve stimulation effects on detrusor overactivity 
incontinence are not due to a placebo effect: a randomized, double-blind, 
placebo controlled trial. J Urol. 2010;184(5):2001–2006.
36. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial 
of percutaneous tibial nerve stimulation versus Sham efficacy in the 
treatment of overactive bladder syndrome: results from the SUmiT trial. 
J Urol. 2010;183(4):1438–1443.
37. van Balken MR, Vandoninck V, Gisolf KW, et al. Posterior tibial nerve 
stimulation as neuromodulative treatment of lower urinary tract dysfunc-
tion. J Urol. 2001;166(3):914–918.
38. Vandoninck V, Van Balken MR, Finazzi Agro E, et al. Posterior tibial 
nerve stimulation in the treatment of urge incontinence. Neurourol 
Urodyn. 2003;22(1):17–23.
39. van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Kiemeney 
LA, Bemelmans BL. Correlation between quality of life and voiding 
variables in patients treated with percutaneous tibial nerve stimulation. 
BJU Int. 2006;97(1):113–116.
40. Fjorback MV, van Rey FS, van der Pal F, Rijkhoff NJ, Petersen T, Heesak-
kers JP. Acute urodynamic effects of posterior tibial nerve stimulation 
on neurogenic detrusor overactivity in patients with MS. Eur Urol. 
2007;51(2):464–470; discussion 471–462.
41. Kabay SC, Yucel M, Kabay S. Acute effect of posterior tibial nerve 
stimulation on neurogenic detrusor overactivity in patients with multiple 
sclerosis: urodynamic study. Urology. 2008;71(4):641–645.
42. Vandoninck V, van Balken MR, Finazzi Agro E, et al. Percutaneous tibial 
nerve stimulation in the treatment of overactive bladder: urodynamic 
data. Neurourol Urodyn. 2003;22(3):227–232.
43. Klingler HC, Pycha A, Schmidbauer J, Marberger M. Use of peripheral 
neuromodulation of the S3 region for treatment of detrusor overactivity: 
a urodynamic-based study. Urology. 2000;56(5):766–771.
44. Yoong W, Shah P, Dadswell R, Green L. Sustained effectiveness of 
percutaneous tibial nerve stimulation for overactive bladder syndrome: 
2-year follow-up of positive responders. Int Urogynecol J. 2013;24(5): 
795–799.
45. van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemel-
mans BL. Percutaneous tibial nerve stimulation in the treatment of 
refractory overactive bladder syndrome: is maintenance treatment 
necessary? BJU Int. 2006;97(3):547–550.
 46. Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Per-
cutaneous tibial nerve stimulation for the long-term treatment of overactive 
bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–2201.
47. Canbaz Kabay S, Kabay S, Mestan E, et al. Long term sustained 
therapeutic effects of percutaneous posterior tibial nerve stimulation 
treatment of neurogenic overactive bladder in multiple sclerosis patients: 
12-months results. Neurourol Urodyn. 2017;36(1):104–110.
48. MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability 
of percutaneous tibial nerve stimulation for the treatment of overactive 
bladder. J Urol. 2010;183(1):234–240.
49. Preyer O, Umek W, Laml T, et al. Percutaneous tibial nerve stimula-
tion versus tolterodine for overactive bladder in women: a randomised 
controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–56.
50. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial 
of percutaneous tibial nerve stimulation versus extended-release tolt-
erodine: results from the overactive bladder innovative therapy trial. J 
Urol. 2009;182(3):1055–1061.
51. Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara 
V. Solifenacin succinate versus percutaneous tibial nerve stimulation 
in women with overactive bladder syndrome: results of a random-
ized controlled crossover study. Gynecol Obstet Invest. 2013;75(4): 
230–234.
52. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus 
non-drug active therapies for non-neurogenic overactive bladder syn-
drome in adults. Cochrane Database Syst Rev. 2012;12:CD003193.
53. Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. 
Electrical stimulation with non-implanted electrodes for overactive 
bladder in adults. Cochrane Database Syst Rev. 2016;12:CD010098.
54. Sancaktar M, Ceyhan ST, Akyol I, et al. The outcome of adding 
peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-
muscarinic therapy in women with severe overactive bladder. Gynecol 
Endocrinol. 2010;26(10):729–732.
55. Karademir K, Baykal K, Sen B, Senkul T, Iseri C, Erden D. A peripheric 
neuromodulation technique for curing detrusor overactivity: Stoller 
afferent neurostimulation. Scand J Urol Nephrol. 2005;39(3):230–233.
56. Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and 
randomized comparison of electrical stimulation of the posterior tibial 
nerve versus oxybutynin versus their combination for treatment of 
women with overactive bladder syndrome. World J Urol. 2014;32(1): 
179–184.
57. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with 
overactive bladder pharmacotherapy in a Medicaid population. Am J 
Manag Care. 2005;11(4 Suppl):S121–S129.
58. van Balken MR, Vergunst H, Bemelmans BL. Prognostic factors 
for successful percutaneous tibial nerve stimulation. Eur Urol. 
2006;49(2):360–365.
59. Beusterien K, Kennelly MJ, Bridges JF, Amos K, Williams MJ, Vasavada 
S. Use of best-worst scaling to assess patient perceptions of treatments 
for refractory overactive bladder. Neurourol Urodyn. 2016;35(8): 
1028–1033.
60. Hashim H, Beusterien K, Bridges JF, Amos K, Cardozo L. Patient 
preferences for treating refractory overactive bladder in the UK. Int 
Urol Nephrol. 2015;47(10):1619–1627.
61. Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Cost-
effectiveness analysis of sacral neuromodulation and botulinum toxin 
A treatment for patients with idiopathic overactive bladder. BJU Int. 
2011;108(4):558–564.
62. Bertapelle MP, Vottero M, Popolo GD, et al. Sacral neuromodulation 
and botulinum toxin A for refractory idiopathic overactive bladder: a 
cost-utility analysis in the perspective of Italian Healthcare System. 
World J Urol. 2015;33(8):1109–1117.
63. Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. 
Percutaneous tibial nerve stimulation: a clinically and cost effective 
addition to the overactive bladder algorithm of care. Curr Urol Rep. 
2012;13(5):327–334.
64. Martinson M, MacDiarmid S, Black E. Cost of neuromodulation 
therapies for overactive bladder: percutaneous tibial nerve stimulation 
versus sacral nerve stimulation. J Urol. 2013;189(1):210–216.
65. Andrews BJ, Reynard JM. Transcutaneous posterior tibial nerve stimula-
tion for treatment of detrusor hyperreflexia in spinal cord injury. J Urol. 
2003;170(3):926.
66. van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemel-
mans BL. Implant-driven tibial nerve stimulation in the treatment of 
refractory overactive bladder syndrome: 12-month follow-up. Neuro-
modulation. 2006;9(2):163–171.
67. Janssen DA, Farag F, Heesakkers JP. Urgent-SQ implant in treatment 
of overactive bladder syndrome: 9-year follow-up study. Neurourol 
Urodyn. 2013;32(5):472–475.
68. van Breda HM, Martens FM, Tromp J, Heesakkers JP. A new implanted 
posterior tibial nerve stimulator for the treatment of overactive bladder 
syndrome: 3-month results of a novel therapy at a single center. J Urol. 
2017;198(1):205–210.
69. De Gennaro M, Capitanucci ML, Mastracci P, Silveri M, Gatti C, 
Mosiello G. Percutaneous tibial nerve neuromodulation is well tolerated 
in children and effective for treating refractory vesical dysfunction. 
J Urol. 2004;171(5):1911–1913.
70. Boudaoud N, Binet A, Line A, et al. Management of refractory overac-
tive bladder in children by transcutaneous posterior tibial nerve stimula-
tion: a controlled study. J Pediatr Urol. 2015;11(3):138 e131–138 e110.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 U
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 0
6-
De
c-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Urology 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Research and Reports in Urology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/research-and-reports-in-urology-journal
Research and Reports in Urology is an international, peer-reviewed, 
open access journal publishing original research, reports, editorials, 
reviews and commentaries on all aspects of adult and pediatric urology 
in the clinic and laboratory including the following topics: Pathology, 
pathophysiology of urological disease; Investigation and treatment of 
urological disease; Pharmacology of drugs used for the treatment of 
urological disease. The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Dovepress
157
PTNS treatment for OAB
71. Hagstroem S, Mahler B, Madsen B, Djurhuus JC, Rittig S. Transcuta-
neous electrical nerve stimulation for refractory daytime urinary urge 
incontinence. J Urol. 2009;182(4 Suppl):2072–2078.
72. Borch L, Rittig S, Kamperis K, Mahler B, Djurhuus JC, Hagstroem S. 
No immediate effect on urodynamic parameters during transcutaneous 
electrical nerve stimulation (TENS) in children with overactive blad-
der and daytime incontinence – a randomized, double-blind, placebo-
controlled study. Neurourol Urodyn. 2016:1–7.
73. Sillen U, Arwidsson C, Doroszkiewicz M, et al. Effects of transcuta-
neous neuromodulation (TENS) on overactive bladder symptoms in 
children: a randomized controlled trial. J Pediatr Urol. 2014;10(6): 
1100–1105.
74. Capitanucci ML, Camanni D, Demelas F, Mosiello G, Zaccara A, De 
Gennaro M. Long-term efficacy of percutaneous tibial nerve stimula-
tion for different types of lower urinary tract dysfunction in children. 
J Urol. 2009;182(4 Suppl):2056–2061.
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 U
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
14
9 
on
 0
6-
De
c-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
